Bresat Cancer Update
Oncology Leader CommentarySpecial FeaturesPrevious Issues

Home: Oncology Leader Commentary: Craig Hederson, MD

Click on the topic below for comments by Dr Craig Henderson to comment on. You will also find links to related articles and clinical trials.

Historical perspective on adjuvant endocrine therapy
More recent trials of adjuvant ovarian ablation
Intergroup trial of adjuvant endocrine therapy
Is tamoxifen more effective in a low estrogen environment
Zoladex plus tamoxifen as adjuvant therapy
Choosing a method of ovarian ablation
Age and menopausal status
Adjuvant chemotherapy and the ovaries
Emotional issues in decision-making
Combining tamoxifen and an aromatase inhibitor in postmenopausal women
Taxanes as adjuvant therapy
Nodal status and choice of adjuvant systemic therapy
Timing of radiation therapy with AC-Taxol
Dose of adjuvant chemotherapy
Liposomal delivery of cytotoxics


Liposomal delivery of cytotoxics

Interview with Neil Love, MD from Breast Cancer Update for Medical Oncologists, Program 2 2000

Play Audio Below:

The thing that I started working on it in the program at UCSF when I went out there. I was pretty skeptical about liposomes and what liposomes would do. And Chris Benz wanted to work on immunoliposomes. That is, taking a liposome that had this polyethylene glycol on the outside of it and attaching the HER 2 monoclonal or part of it, the FAB 2 of a HER2, to the outer surface and using that as a targeting technique. Well, I was pretty skeptical to begin with, but gradually got more and more interested in this to the point where I spent all of my time doing this – went to the company that actually had the patent for it. Because I found the pre-clinical data very compelling – that you could, in fact, use the physical characteristics of this delivery system to get higher drug doses to the tumor than you do to the normal tissues. And I think the proof of principle is very clear in all the pre-clinical models. I think its pretty clear in Kaposi’s sarcoma and I think that we’re gradually building up the data in the clinic. Excellent data on ovarian cancer with Doxil and its like the whole issue with the high dose therapy. I mean, we started on those concepts in the ‘60s; we started doing uncontrolled trials in the ‘70s; we started doing the randomized trials in the mid-‘80s; it takes a long time to fully test a concept like that. And we’re far from doing that with this delivery system, but certainly the study of Doxil was very consistent with what I’ve done throughout most of my career.

Relevant Articles:

Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma.
Lyass, O.; Uziely, B.; Ben-Yosef, R.; Tzemach, D.; Heshing, N. I.; Lotem, M.; Brufman, G., and Gabizon, A. Cancer. 89(5):1037-1047, 2000 Sep 1.

Relevant Clinical Trials:

Phase II Study of Doxorubicin HCl Liposome and Docetaxel With or Without Trastuzumab (Herceptin) in Women With Metastatic Breast Cancer (Summary Last Modified 12/2000)

Phase I/II Study of Doxorubicin HCL Liposome and Trastuzumab (Herceptin) in Women With Locally Advanced, Inflammatory, or Metastatic Breast Cancer

Phase II Randomized Study of Two Different Dose Schedules of Doxorubicin HCl Liposome in Women With Metastatic Breast Cancer

Phase II Study of Gemcitabine and Doxorubicin HCl Liposome in Women With Metastatic Breast Cancer

Top of Page

 

Home · Contact us
Terms of use and general disclaimer